Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 14/20 | 0.46 |
| ▸ | ANPEP | P15144 | 6/20 | 0.46 |
| ▸ | PEPD | P12955 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.36 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3012517 | 0.86 | PEPD (0.39) | MMP2ANPEPPEPDPOLBDPP4 | |
| SCHEMBL21199412 | 0.82 | PEPD (0.37) | MMP2ANPEPPEPDPOLBDPP4 | |
| SCHEMBL16300657 | 0.82 | DPP4 (0.34) | DPP4DPP8DPP7EPHX2CNR2 | |
| SCHEMBL32683359 | 0.81 | DPP4 (0.41) | MMP2ANPEPPEPDPOLBDPP4 | |
| SCHEMBL19083941 | 0.80 | ATM (0.43) | POLBDPP4DPP8DPP7CNR2 | |
| SCHEMBL2207075 | 0.80 | PTPN1 (0.40) | PEPDPOLBDPP4DPP8DPP7 | |
| SCHEMBL1701540 | 0.80 | PTPN1 (0.40) | PEPDPOLBDPP4DPP8DPP7 | |
| SCHEMBL706243 | 0.80 | PTPN1 (0.40) | PEPDPOLBDPP4DPP8DPP7 | |
| SCHEMBL29142179 | 0.79 | POLB (0.36) | MMP2ANPEPPEPDPOLBDPP4 | |
| SCHEMBL29142178 | 0.79 | POLB (0.36) | MMP2ANPEPPEPDPOLBDPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260069602-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | ACONCAGUA BIO INC (US) | 2026-03-12 | — | — | US | disclosed |
| US-RE43298-E1 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2012-04-03 | — | — | US | disclosed |
| US-20110117057-A1 | NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | SCHERING CORPORATION (US) | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110117057-A1 | NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | HPN, TMPRSS15, VIP | MMP2 425/4885ANPEP 22/4885PEPD 12/4885 |
| US-20260069602-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | SCTR, SSTR1, NPY1R | MMP2 4076/4885ANPEP 1026/4885PEPD 3115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.